Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events

Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, 12, 252, 10.1038/nrc3239

Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466

Motzer, 2018, Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma, N Engl J Med, 378, 1277, 10.1056/NEJMoa1712126

Hamid, 2019, Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001, Ann Oncol, 30, 582, 10.1093/annonc/mdz011

Postow, 2018, Immune-related adverse events associated with immune checkpoint blockade, N Engl J Med, 378, 158, 10.1056/NEJMra1703481

Herrmann, 2020, Immune checkpoint inhibitors and immune-related adverse renal events, Kidney Int Rep, 5, 1139, 10.1016/j.ekir.2020.04.018

Larkin, 2015, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, N Engl J Med, 373, 23, 10.1056/NEJMoa1504030

Wolchok, 2017, Overall survival with combined nivolumab and ipilimumab in advanced melanoma, N Engl J Med, 377, 1345, 10.1056/NEJMoa1709684

Haanen, 2017, Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 28, iv119, 10.1093/annonc/mdx225

Cortazar, 2016, Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors, Kidney Int, 90, 638, 10.1016/j.kint.2016.04.008

Shirali, 2016, Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients, Am J Kidney Dis, 68, 287, 10.1053/j.ajkd.2016.02.057

Mamlouk, 2019, Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience, J Immunother Cancer, 7, 2, 10.1186/s40425-018-0478-8

Seethapathy, 2019, The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors, Clin J Am Soc Nephrol, 14, 1692, 10.2215/CJN.00990119

Manohar, 2020, Acute interstitial nephritis and checkpoint inhibitor therapy, Single Center Experience of Management and Drug Rechallenge, 1, 16

Meraz-Muñoz, 2020, Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes, J Immunother Cancer, 8

Cortazar, 2020, Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study, J Am Soc Nephrol, 31, 435, 10.1681/ASN.2019070676

Kitchlu, 2019, Acute kidney injury in patients receiving systemic treatment for cancer: a population-based cohort study, J Natl Cancer Inst, 111, 727, 10.1093/jnci/djy167

Thompson, 2019, Management of immunotherapy-related toxicities, version 1.2019, J Natl Compr Canc Netw, 17, 255, 10.6004/jnccn.2019.0013

Khwaja, 2012, KDIGO clinical practice guidelines for acute kidney injury, Nephron Clin Pract, 120, c179, 10.1159/000339789

Nakamura, 2019, Biomarkers for immune checkpoint inhibitor-mediated tumor response and adverse events, Front Med (Lausanne), 6, 119, 10.3389/fmed.2019.00119

von Itzstein, 2020, Investigational biomarkers for checkpoint inhibitor immune-related adverse event prediction and diagnosis, Clin Chem, 66, 779, 10.1093/clinchem/hvaa081

Abolhassani, 2019, C-reactive protein as an early marker of immune-related adverse events, J Cancer Res Clin Oncol, 145, 2625, 10.1007/s00432-019-03002-1

Kirsztajn, 2002, Urinary retinol-binding protein as a prognostic marker in glomerulopathies, Nephron, 90, 424, 10.1159/000054730

Domingos, 2016, Urinary retinol-binding protein: relationship to renal function and cardiovascular risk factors in chronic kidney disease, PLoS One, 11, 10.1371/journal.pone.0162782

Norden, 2014, Urine retinol-binding protein 4: a functional biomarker of the proximal renal tubule, Adv Clin Chem, 63, 85, 10.1016/B978-0-12-800094-6.00003-0

Manohar, 2019, Interstitial nephritis in immune checkpoint inhibitor therapy, Kidney Int, 96, 252, 10.1016/j.kint.2018.11.009

Oleas, 2020, Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience, Clin Kidney J, sfaa008

Muriithi, 2014, Biopsy-proven acute interstitial nephritis, 1993–2011: a case series, Am J Kidney Dis, 64, 558, 10.1053/j.ajkd.2014.04.027

Izzedine, 2019, Renal toxicities associated with pembrolizumab, Clin Kidney J, 12, 81, 10.1093/ckj/sfy100